JEFFREY MEYER: Open Payments
NPI 1962559377 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$844 in 28 payments from 14 companies in 2025. Trend: 2023 $1,270 · 2024 $1,242 · 2025 $844
Food & beverage: $844
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $170 |
| Alkermes, Inc. | 6 | $165 |
| E.R. Squibb & Sons, L.L.C. | 1 | $106 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| ABBVIE INC. | 2 | $39 |
| Lundbeck LLC | 1 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
Products named: SPRAVATO, ARISTADA, COBENFY, INGREZZA, REXULTI, AUSTEDO XR, HETLIOZ, VRAYLAR.
Industry payments across MO — which companies pay providers there.
